Drug Development

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Oxidative stress (OS) is implicated in vascular mild cognitive impairment (vMCI).
• N-acetylcysteine (NAC), an antioxidant, was investigated for its potential to mitigate cognitive decline in vMCI.
• A prior randomized clinical trial showed no significant overall effect of NAC on executive function in vMCI patients.

Purpose of the Study:

• To identify clinical predictors of response to N-acetylcysteine (NAC) in patients with vascular mild cognitive impairment (vMCI).
• To explore heterogeneity in treatment effects of NAC on executive function in vMCI.
• To inform personalized therapeutic strategies for vMCI targeting oxidative stress.

Main Methods:

• A 24-week randomized clinical trial involving vMCI patients.
• Baseline clinical variables were assessed for their impact on executive function changes with NAC versus placebo.
• Multivariate regression and quartile-based analysis were used to identify predictors and stratify treatment effects.

Main Results:

• Younger age, higher BMI, non-APOE4 status, lower apathy scores, elevated homocysteine, and ACE inhibitor use predicted better executive function improvement with NAC.
• Treatment effects varied significantly across quartiles of predicted response (p<0.001).
• Response rates in the highest quartile of predicted benefit reached 100%.

Conclusions:

• Significant variability exists in NAC response among vMCI patients.
• Certain subgroups demonstrate more substantial benefits from NAC, suggesting potential for personalized treatment.
• These findings underscore the need for tailored approaches to managing oxidative stress in vMCI.